Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Your provider tracks lean mass, fat mass, and functional markers to ensure your treatment is producing the right kind of weight loss
You might feel an opening around the heart
Most people tolerate a supervised drip well and feel no lasting effects
Table of Contents What Is Retatrutide and Its Current Development Status in the UK Risks of Sourcing Unregulated Peptides Online MHRA Guidance on Unlicensed Weight Loss Treatments Approved Alternatives Available Through NHS and Private Clinics How to Speak to a UK Doctor About Emerging Weight Loss Options Scientific References Frequently Asked Questions What Is Retatrutide and Its Current Development Status in the UK Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that remains in Phase 3 trials and holds no MHRA marketing authorisation as of mid-2025
Under the electron microscope, mild mitochondrial swelling, increased volume, local fragmentation and reduction of cristae, and local dissolution of the intramembrane matrix, and mitochondrial micro-autonomy can be seen in the visual field
US$ 22.14
US$ 25.11
US$ 21.45
